Clinical Study: Analysis of Glycemic Control and Satisfaction With a Connected Smart Cap in Patients With Type 1 Diabetes Mellitus

Phase

Condition

Diabetes And Hypertension

Diabetes Prevention

Diabetes Mellitus, Type 1

Treatment

CONNECTED SMART CAP

Clinical Study ID

NCT06845891

5350

Ages > 18
All Genders

Study Summary

This clinical study evaluates the impact of the Cap INSULCLOCK device on glycemic control, treatment adherence, and patient satisfaction in adults with type 1 diabetes mellitus (T1DM). Despite advances in pharmacology and technology, a significant proportion of individuals with T1DM fail to achieve recommended glycemic targets, partly due to the complexity of insulin therapy and suboptimal adherence. Cap INSULCLOCK is a device that attaches to insulin pens, automatically recording injections and integrating data on glucose levels, insulin administration, food intake, and physical activity, with real-time Bluetooth transmission. Its use may enhance adherence and optimize metabolic control.

This study is a randomized, low-intervention clinical trial conducted at a single center, enrolling 42 patients, who will be randomized into two groups: one using the activated device and a control group using the device in a blinded mode. The primary objective is to assess differences in time above range (TAR >180 mg/dL) over the last 14 days of continuous glucose monitoring (CGM). Secondary objectives include evaluating HbA1c levels, time in range (TIR), frequency of hypoglycemic episodes, and patient satisfaction. Data will be analyzed using advanced statistical methods, and the intervention is expected to improve adherence, reduce glycemic variability, and enhance quality of life in individuals with T1DM

Eligibility Criteria

Inclusion

Inclusion Criteria:

Men and women aged 18 years or older.
Diagnosis of type 1 diabetes mellitus (T1DM).
Users of flash continuous glucose monitoring (FGM) sensors with >70% of recordeddata, including intake and insulin dose logs.
Adequate therapeutic adherence, with no missed appointments in the past year.
Time above range (TAR >180 mg/dL) >25%.
Ability to provide informed consent to participate in the study.
Access to technology for follow-up, including a smartphone with internetconnectivity and compatibility with the Insulcloud app.

Exclusion

Exclusion Criteria:

Current pregnancy.
Severe acute illness.
Exclusion criteria for the use of real-time continuous glucose monitoring (RT-CGM)systems as per the Framework Agreement of the Community of Madrid for RT-CGM use (SERMAS).
Inability to provide informed consent or to meet the study requirements for anyreason.

Study Design